Biotech entity
All 2 tracked stories fall under one category: pharma. Of the tracked stories, 2 of 2 also mention ViiV Healthcare, the most common co-covered peer. Source depth averages 2 original sources per story, versus 4.5 across the same-window beat baseline.
Last mentioned: Aug 13, 2026
Entity pulse
Coverage balance Balanced directional read. Positive and negative coverage are within 0 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 2 tracked stories fall under one category: pharma. Of the tracked stories, 2 of 2 also mention ViiV Healthcare, the most common co-covered peer. Source depth averages 2 original sources per story, versus 4.5 across the same-window beat baseline. Their average consequence score of 6 sits level with the 6 recorded across the beat in that window. This profile follows 2 Biotech stories mentioning Gilead Sciences across the period from March 13, 2026 to March 17, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 63 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Gilead Sciences. Shared-story counts are live from our verified record — not editorial picks.
New Limits Reported
States begin implementing restrictive eligibility and waitlists for drug assistance programs.
Fiscal Pressure Mounts
Rising costs of long-acting therapies and expiration of pandemic funding strain state budgets.
Waitlist Peak
National ADAP waitlists reached a record high of over 9,000 individuals following the Great Recession.
Ryan White CARE Act
Federal legislation established to provide a safety net for HIV/AIDS care and treatment.
Several states have begun implementing restrictive eligibility requirements and waitlists for AIDS Drug Assistance Programs (ADAPs), citing budgetary shortfalls and rising medication costs. This shift threatens to reverse years of progress in HIV viral suppression and places significant financial pressure on low-income patients and safety-net providers.
The Florida Legislature has approved a stopgap bill to restore essential funding to the state's AIDS Drug Assistance Program (ADAP), averting a potential crisis in medication access. This legislative action ensures that thousands of low-income residents living with HIV/AIDS will continue to receive life-saving antiretroviral treatments without interruption.
Gilead Sciences is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
